Demyelinating Disorders clinical trials

Explore recruiting demyelinating disorders clinical trials.

Recruiting demyelinating disorders studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Demyelinating Disorders trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system

Germany, Austria

Phase II and Phase III (Integrated) EU CTIS Study details

Demyelinating Disorders trials by city

Demyelinating Disorders clinical trials

Recruiting demyelinating disorders studies right now

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Efficacy of Split Gait in the Treatment of Dynamic Asymmetries in Subjects With Pathologic Claudication

The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders

Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD)

The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders

High-Tech Rehabilitation Pathway for Acute Adult Neuromuscular Diseases - Fit4MedRob-Acute MND Project

Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET)

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

Assessing NHS ImplemeNTation of an onlinE Resilience Training Acceptance and Commitment Therapy (ACT) Programme to Prevent Job Loss in Multiple Sclerosis

Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis

Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

Also recruiting in Europe

A multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system

Demyelinating Disorders trials by city

Other conditions